Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A6 | Q3KNW5 | 3/20 | 0.81 |
| ▸ | SLC10A2 | Q12908 | 2/20 | 0.81 |
| ▸ | SLC10A1 | Q14973 | 2/20 | 0.81 |
| ▸ | GPR27 | Q9NS67 | 7/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.62 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | ACLY | P53396 | 1/20 | 0.57 |
| ▸ | METAP2 | P50579 | 2/20 | 0.56 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6760783 | 0.95 | SLC10A6 (0.74) | SLC10A6SLC10A2SLC10A1GPR27KDM4E | |
| SCHEMBL492157 | 0.94 | SLC10A6 (0.72) | SLC10A6SLC10A2SLC10A1GPR27KDM4E | |
| SCHEMBL491711 | 0.94 | SLC10A6 (0.72) | SLC10A6SLC10A2SLC10A1GPR27KDM4E | |
| SCHEMBL7844614 | 0.94 | SLC10A6 (0.72) | SLC10A6SLC10A2SLC10A1GPR27KDM4E | |
| SCHEMBL491625 | 0.94 | SLC10A6 (0.72) | SLC10A6SLC10A2SLC10A1GPR27KDM4E | |
| SCHEMBL5115455 | 0.94 | SLC10A6 (0.88) | SLC10A6SLC10A2SLC10A1GPR27KDM4E | |
| SCHEMBL6862400 | 0.93 | SLC10A6 (0.71) | SLC10A6SLC10A2SLC10A1GPR27KDM4E | |
| SCHEMBL5126855 | 0.93 | SLC10A6 (0.71) | SLC10A6SLC10A2SLC10A1GPR27KDM4E | |
| SCHEMBL5114385 | 0.92 | SLC10A6 (0.69) | SLC10A6SLC10A2SLC10A1GPR27KDM4E | |
| SCHEMBL491906 | 0.92 | SLC10A6 (0.69) | SLC10A6SLC10A2SLC10A1GPR27KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040167180-A1 | Methods for anti-tumor therapy | COMPASS PHARMACEUTICALS, LLC | 2004-08-26 | — | — | US | claimed |
| US-6716879-B2 | ADMINISTERING AN EFFECTIVE AMOUNT OF SULFONYLAMINO-SUBSTITUTED N-ARYL- OR HETEROACRYL OR ALKYL OR CYCLOALKYLCARBOXAMIDE DERIVATIVES OR SALTS, ESTERS, AMIDES OR PRODRUG TO TREAT TUMOR | COMPASS PHARMACEUTICALS, LLC | 2004-04-06 | — | — | US | claimed |
| EP-1317260-A2 | METHODS FOR TREATING TUMORS USING SULFONYL COMPOUNDS | Signature Bioscience, Inc. (US) | 2003-06-11 | — | — | EP | claimed |
| EP-1187531-A4 | MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2003-05-28 | — | — | EP | claimed |
| US-6458845-B1 | METHOD OF ANTAGONIZING A MACROPHAGE SCAVENGER RECEPTOR COMPRISING ADMINISTERING TO A SUBJECT IN NEED OF TREATMENT AN EFFECTIVE AMOUNT OF AN N-PHENYL-2-(3-TRIFLUOROMETHYLPHENYLSULFONAMIDO)BENZAMIDE, A | SMITHKLINE BEECHAM CORPORATION | 2002-10-01 | — | — | US | claimed |
| CN-1358062-A | Macrophage scavenger receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 2002-07-10 | — | — | CN | claimed |
| US-20020082243-A1 | Methods for anti-tumor therapy | PHOENIX ONCOLOGY, LLC | 2002-06-27 | — | — | US | claimed |
| EP-1187531-A1 | MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-03-20 | — | — | EP | claimed |
| WO-2002017897-A2 | METHODS FOR TREATING TUMORS USING SULFONYL COMPOUNDS | PRIMECYTE, INC. (US) | 2002-03-07 | — | — | WO | claimed |
| WO-2001098264-A1 | MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-12-27 | — | — | WO | claimed |
| WO-2000078145-A1 | MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-28 | — | — | WO | claimed |
| US-20040167180-A1 | Methods for anti-tumor therapy | COMPASS PHARMACEUTICALS, LLC | 2004-08-26 | — | — | US | disclosed |
| US-6716879-B2 | ADMINISTERING AN EFFECTIVE AMOUNT OF SULFONYLAMINO-SUBSTITUTED N-ARYL- OR HETEROACRYL OR ALKYL OR CYCLOALKYLCARBOXAMIDE DERIVATIVES OR SALTS, ESTERS, AMIDES OR PRODRUG TO TREAT TUMOR | COMPASS PHARMACEUTICALS, LLC | 2004-04-06 | — | — | US | disclosed |
| EP-1317260-A2 | METHODS FOR TREATING TUMORS USING SULFONYL COMPOUNDS | Signature Bioscience, Inc. (US) | 2003-06-11 | — | — | EP | disclosed |
| EP-1187531-A4 | MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20020082243-A1 | Methods for anti-tumor therapy | PHOENIX ONCOLOGY, LLC | 2002-06-27 | — | — | US | disclosed |
| EP-1187531-A1 | MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-03-20 | — | — | EP | disclosed |
| WO-2002017897-A2 | METHODS FOR TREATING TUMORS USING SULFONYL COMPOUNDS | PRIMECYTE, INC. (US) | 2002-03-07 | — | — | WO | disclosed |
| WO-2001098264-A1 | MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-12-27 | — | — | WO | disclosed |
| WO-2000078145-A1 | MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082243-A1 | Methods for anti-tumor therapy | HCCS, PAICS, TP53 | SLC10A6 1719/4885SLC10A2 846/4885SLC10A1 941/4885 |
| US-20040167180-A1 | Methods for anti-tumor therapy | HCCS, PAICS, TP53 | SLC10A6 1719/4885SLC10A2 846/4885SLC10A1 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.